Akribes Biomedical is dedicated to the improvement of chronic wound therapy. We developed the first theranostic assay platform to enable personalized pharmacological therapy of chronic wounds. Based on this platform we identified and patented drugs with so far unknown potential for chronic wound healing, which will be developed as novel wound therapeutics.
R&D:Akribes Biomedical has developed proprietary cellular assay systems, using wound exudates from patients. Exudates (fluids) from chronic wounds damage and even kill primary human cell cultures. The assays are able to characterize wounds of different etiologies and to demonstrate the progression from a chronic to a healing wound in individual patients. They are used to identify and profile the potential of compounds to revert a non-healing to a healing wound phenotype.